Acamprosate

  • IUPAC: 3- Acetamidopropan -1-sulfonic
  • N- Acetylhomotaurin
  • Latin: Acamprosatum
  • C5H11NO4S ( acamprosate )
  • C10H20CaN2O8S2 ( acamprosate calcium · )
  • 77337-76-9 ( acamprosate )
  • 77337-73-6 ( acamprosate calcium · )

N07BB03

Adjuvant therapeutic agent for alcohol withdrawal

270 ° C ( acamprosate calcium · )

Poorly in water (5 g · l-1 at 20 ° C, calcium salt)

Attention

> 10000 mg · kg -1 ( LD50, Mouse, oral, acamprosate calcium · )

Template: Infobox chemical / molecular formula search available

Acamprosate is a drug which is used in the adjuvant treatment of alcoholism.

Which is also referred to as N- Acetylhomotaurin substance is related to the active amino acids in the brain neurotransmitter γ -aminobutyric acid ( GABA), glutamate, and taurine.

Action principle

Acamprosate attenuates triggered by the neurotransmitter glutamate hyperexcitability of the brain by occupying the receptors of nerve cells, thereby interfering with the binding of glutamate molecules.

Since alcoholics have particularly much glutamate in the brain (the reason is unclear), acamprosate is used in the ( outpatient ) treatment of alcoholism, to the desire to cut down on alcohol. Not everyone reacts to acamprosate alcohol addicts. Acamprosate is not suitable for the treatment of symptoms of alcohol withdrawal.

History of development

1984 acamprosate was developed by the small French firm Meram for the treatment of epilepsy and alcohol addicts. In 1987 Meram received a preliminary approval for the substance in France. In 1989, the company has brought the drug on the market there. To prepare for the EU-wide approval, the French company has Lipha (a subsidiary of Merck KGaA) over the substance and conducted twelve placebo-controlled, multicenter studies with a total of about 4000 patients. In December 1995, the approval of Campral in Germany took place. In 1996, a mid-March Lipha acamprosate - containing medicine than Campral ® on the German market. In July 2004, Campral ® was " allowed to maintain alcohol abstinence in alcohol-dependent patients who already are alcohol- abstinent at the start of treatment " in the United States, sales partners in the U.S. Forest Laboratories. 1999 got the Campral Galen von Pergamon Prize.

Anti- Craving

Acamprosate is used as an anti- craving substance - substance in alcohol withdrawal. The patient should be abstinent before taking about 5 days. The concomitant use of acamprosate and alcohol does not change the pharmacokinetics of acamprosate nor that of the alcohol.

Side effects

Common side effects include diarrhea ( diarrhea ), flatulence (wind ), nausea and vomiting, itching and rash. Acamprosate does not affect the ability to drive, a potential for addiction is not known.

Interactions

Interactions with other drugs or alcohol are not expected.

Pharmaceutical information

Acamprosate is orally active. Is used medicinally, the calcium salt.

Trade names

Acamprosate is available under the name Campral commercially available in Germany, Austria and Switzerland.

CAS registry number PubChem Anatomical Therapeutic Chemical Classification System DrugBank Dangerous Substances Directive (67/548/EEC) Active ingredient Semiochemical Berliner Zeitung Bernhard van Treeck
26399
de